This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here After-Hours Headlines

NEW YORK ( TheStreet) -- Here's the rundown on companies making news after Thursday's closing bell.

Shares of (CRM - Get Report) jumped 7.2% to $143.49 on volume of nearly 800,000, according to, after the cloud and software technology company reported non-GAAP earnings of $54.5 million, or 37 cents a share, on revenue of $695.5 million for its fiscal first quarter.

The average estimate of analysts polled by Thomson Reuters was for a profit of 34 cents a share on revenue of $678.2 million in the April-ended period. also forecast non-GAAP earnings of 38 to 39 cents a share for the second quarter ending in July vs. Wall Street's consensus view for a profit of 38 cents a share.

Marvell Technology

Marvell Technology (MRVL - Get Report) was a winner in Thursday's extended session after the Santa Clara, Calif.-based chip maker reported better than expected quarterly results, initiated a dividend and boosted its buyback program.

The company reported non-GAAP earnings of $139 million, or 23 cents a share, for the first quarter on revenue of $796.4 million, besting the average analysts' view of for a profit of 20 cents a share on revenue of $768.7 million.

Marvell also said its board has approved a quarterly dividend of 6 cents a share and increased its repurchase authorization by $500 million to $2.5 billion. The stock was last quoted at $13.80, up 3.8%. on volume of more than 500,000.


Shares of Sequenom (SQNM - Get Report) were down in late trades after the company said Coventry Health Care (CVH) has opted to terminate a coverage agreement between the two companies.

Sequenom said Coventry had opted to terminate the agreement without cause effective August 31, and that it advised that "this decision was not a judgment" on Sequenom or its products. The deal would have provided coverage for Sequenom's MaterniT21 PLUS laboratory-developed test and other similar products within Coventry's network.

The stock was last quoted at $4.40, off 7.8%, on volume of nearly 90,000, according to
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ARO $0.20 0.00%
CRM $58.51 0.00%
FB $104.07 0.00%
MRVL $8.96 0.00%
SQNM $1.61 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs